Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population

David J. Kaplan, Stephen A. Boorjian, Karen Ruth, Brian L. Egleston, David Y T Chen, Rosalia Viterbo, Robert G. Uzzo, Mark K. Buyyounouski, Susan Raysor, Veda N. Giri

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: To evaluate the Prostate Cancer Prevention Trial (PCPT) risk calculator in a screening cohort of young, racially diverse, high-risk men with a low baseline prostate-specific antigen (PSA) level and enrolled in the Prostate Cancer Risk Assessment Program (PRAP). The PCPT calculator provides an assessment of prostate cancer risk based on age, PSA level, race, previous biopsy, and family history. Patients and Methods: Eligibility for PRAP includes men aged 35-69 years who are African-American, have a family history of prostate cancer, or have a known BRCA1/2 mutation. PCPT risk scores were determined for PRAP participants, and were compared to observed prostate cancer rates. Results: In all, 624 participants were evaluated, including 382 (61.2%) African-American men and 242 (38.7%) men with a family history of prostate cancer; the median (range) age was 49.0 (34.0-69.0) years and the median PSA level 0.9 (0.1-27.2) ng/mL. The PCPT risk score correlated with prostate cancer diagnosis, as the median baseline risk score in patients diagnosed with prostate cancer was 31.3%, vs 14.2% in patients not diagnosed with prostate cancer (P < 0.001). The PCPT calculator similarly stratified the risk of diagnosis of Gleason score ≥7 disease, as the median risk score was 36.2% in patients diagnosed with Gleason ≥7 prostate cancer vs 15.2% in all other participants (P < 0.001). Conclusion: The PCPT risk calculator score was found to stratify prostate cancer risk in a cohort of young, primarily African-American men with a low baseline PSA level. These Results: support further evaluation of this predictive tool for assessing the risk of prostate cancer in high-risk men.

Original languageEnglish (US)
Pages (from-to)334-337
Number of pages4
JournalBJU International
Volume105
Issue number3
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Population
Prostate-Specific Antigen
African Americans
Neoplasm Grading

Keywords

  • Biopsy
  • Calculator
  • Prediction
  • Prevention
  • Prostate cancer
  • Race

ASJC Scopus subject areas

  • Urology

Cite this

Kaplan, D. J., Boorjian, S. A., Ruth, K., Egleston, B. L., Chen, D. Y. T., Viterbo, R., ... Giri, V. N. (2010). Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population. BJU International, 105(3), 334-337. https://doi.org/10.1111/j.1464-410X.2009.08793.x

Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population. / Kaplan, David J.; Boorjian, Stephen A.; Ruth, Karen; Egleston, Brian L.; Chen, David Y T; Viterbo, Rosalia; Uzzo, Robert G.; Buyyounouski, Mark K.; Raysor, Susan; Giri, Veda N.

In: BJU International, Vol. 105, No. 3, 02.2010, p. 334-337.

Research output: Contribution to journalArticle

Kaplan, DJ, Boorjian, SA, Ruth, K, Egleston, BL, Chen, DYT, Viterbo, R, Uzzo, RG, Buyyounouski, MK, Raysor, S & Giri, VN 2010, 'Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population', BJU International, vol. 105, no. 3, pp. 334-337. https://doi.org/10.1111/j.1464-410X.2009.08793.x
Kaplan, David J. ; Boorjian, Stephen A. ; Ruth, Karen ; Egleston, Brian L. ; Chen, David Y T ; Viterbo, Rosalia ; Uzzo, Robert G. ; Buyyounouski, Mark K. ; Raysor, Susan ; Giri, Veda N. / Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population. In: BJU International. 2010 ; Vol. 105, No. 3. pp. 334-337.
@article{c2aa30e91e6641c7a6de61a9f2a49b1f,
title = "Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population",
abstract = "Objective: To evaluate the Prostate Cancer Prevention Trial (PCPT) risk calculator in a screening cohort of young, racially diverse, high-risk men with a low baseline prostate-specific antigen (PSA) level and enrolled in the Prostate Cancer Risk Assessment Program (PRAP). The PCPT calculator provides an assessment of prostate cancer risk based on age, PSA level, race, previous biopsy, and family history. Patients and Methods: Eligibility for PRAP includes men aged 35-69 years who are African-American, have a family history of prostate cancer, or have a known BRCA1/2 mutation. PCPT risk scores were determined for PRAP participants, and were compared to observed prostate cancer rates. Results: In all, 624 participants were evaluated, including 382 (61.2{\%}) African-American men and 242 (38.7{\%}) men with a family history of prostate cancer; the median (range) age was 49.0 (34.0-69.0) years and the median PSA level 0.9 (0.1-27.2) ng/mL. The PCPT risk score correlated with prostate cancer diagnosis, as the median baseline risk score in patients diagnosed with prostate cancer was 31.3{\%}, vs 14.2{\%} in patients not diagnosed with prostate cancer (P < 0.001). The PCPT calculator similarly stratified the risk of diagnosis of Gleason score ≥7 disease, as the median risk score was 36.2{\%} in patients diagnosed with Gleason ≥7 prostate cancer vs 15.2{\%} in all other participants (P < 0.001). Conclusion: The PCPT risk calculator score was found to stratify prostate cancer risk in a cohort of young, primarily African-American men with a low baseline PSA level. These Results: support further evaluation of this predictive tool for assessing the risk of prostate cancer in high-risk men.",
keywords = "Biopsy, Calculator, Prediction, Prevention, Prostate cancer, Race",
author = "Kaplan, {David J.} and Boorjian, {Stephen A.} and Karen Ruth and Egleston, {Brian L.} and Chen, {David Y T} and Rosalia Viterbo and Uzzo, {Robert G.} and Buyyounouski, {Mark K.} and Susan Raysor and Giri, {Veda N.}",
year = "2010",
month = "2",
doi = "10.1111/j.1464-410X.2009.08793.x",
language = "English (US)",
volume = "105",
pages = "334--337",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population

AU - Kaplan, David J.

AU - Boorjian, Stephen A.

AU - Ruth, Karen

AU - Egleston, Brian L.

AU - Chen, David Y T

AU - Viterbo, Rosalia

AU - Uzzo, Robert G.

AU - Buyyounouski, Mark K.

AU - Raysor, Susan

AU - Giri, Veda N.

PY - 2010/2

Y1 - 2010/2

N2 - Objective: To evaluate the Prostate Cancer Prevention Trial (PCPT) risk calculator in a screening cohort of young, racially diverse, high-risk men with a low baseline prostate-specific antigen (PSA) level and enrolled in the Prostate Cancer Risk Assessment Program (PRAP). The PCPT calculator provides an assessment of prostate cancer risk based on age, PSA level, race, previous biopsy, and family history. Patients and Methods: Eligibility for PRAP includes men aged 35-69 years who are African-American, have a family history of prostate cancer, or have a known BRCA1/2 mutation. PCPT risk scores were determined for PRAP participants, and were compared to observed prostate cancer rates. Results: In all, 624 participants were evaluated, including 382 (61.2%) African-American men and 242 (38.7%) men with a family history of prostate cancer; the median (range) age was 49.0 (34.0-69.0) years and the median PSA level 0.9 (0.1-27.2) ng/mL. The PCPT risk score correlated with prostate cancer diagnosis, as the median baseline risk score in patients diagnosed with prostate cancer was 31.3%, vs 14.2% in patients not diagnosed with prostate cancer (P < 0.001). The PCPT calculator similarly stratified the risk of diagnosis of Gleason score ≥7 disease, as the median risk score was 36.2% in patients diagnosed with Gleason ≥7 prostate cancer vs 15.2% in all other participants (P < 0.001). Conclusion: The PCPT risk calculator score was found to stratify prostate cancer risk in a cohort of young, primarily African-American men with a low baseline PSA level. These Results: support further evaluation of this predictive tool for assessing the risk of prostate cancer in high-risk men.

AB - Objective: To evaluate the Prostate Cancer Prevention Trial (PCPT) risk calculator in a screening cohort of young, racially diverse, high-risk men with a low baseline prostate-specific antigen (PSA) level and enrolled in the Prostate Cancer Risk Assessment Program (PRAP). The PCPT calculator provides an assessment of prostate cancer risk based on age, PSA level, race, previous biopsy, and family history. Patients and Methods: Eligibility for PRAP includes men aged 35-69 years who are African-American, have a family history of prostate cancer, or have a known BRCA1/2 mutation. PCPT risk scores were determined for PRAP participants, and were compared to observed prostate cancer rates. Results: In all, 624 participants were evaluated, including 382 (61.2%) African-American men and 242 (38.7%) men with a family history of prostate cancer; the median (range) age was 49.0 (34.0-69.0) years and the median PSA level 0.9 (0.1-27.2) ng/mL. The PCPT risk score correlated with prostate cancer diagnosis, as the median baseline risk score in patients diagnosed with prostate cancer was 31.3%, vs 14.2% in patients not diagnosed with prostate cancer (P < 0.001). The PCPT calculator similarly stratified the risk of diagnosis of Gleason score ≥7 disease, as the median risk score was 36.2% in patients diagnosed with Gleason ≥7 prostate cancer vs 15.2% in all other participants (P < 0.001). Conclusion: The PCPT risk calculator score was found to stratify prostate cancer risk in a cohort of young, primarily African-American men with a low baseline PSA level. These Results: support further evaluation of this predictive tool for assessing the risk of prostate cancer in high-risk men.

KW - Biopsy

KW - Calculator

KW - Prediction

KW - Prevention

KW - Prostate cancer

KW - Race

UR - http://www.scopus.com/inward/record.url?scp=75149130978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149130978&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2009.08793.x

DO - 10.1111/j.1464-410X.2009.08793.x

M3 - Article

C2 - 19709072

AN - SCOPUS:75149130978

VL - 105

SP - 334

EP - 337

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 3

ER -